A Phase Ib/II Study of Cetuximab and Pembrolizumab in Metastatic Colorectal Cancer
Phase of Trial: Phase I/II
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Cetuximab (Primary) ; Pembrolizumab (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 06 Feb 2018 Planned End Date changed from 13 Jan 2018 to 13 Jan 2020.
- 06 Feb 2018 Planned primary completion date changed from 13 Jan 2018 to 13 Jan 2019.
- 20 Jan 2018 Results(n=9; between 08/10/16 and 11/02/16) assessing safety and clinical activity of cetuximab and pembrolizumab in metastatic colorectal cancer patients, presented at the 2018 Gastrointestinal Cancers Symposium.